Drug
Alks 5461
Alks 5461: highest development phase Phase 3, developed by Alkermes. 5 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Alkermes
Trials
| Drug | Phase | Indication |
|---|---|---|
| ALKS 5461 NCT03610048 | Phase 3 | Refractory Major Depressive Disorder |
| ALKS 5461 NCT02141399 | Phase 3 | Major Depressive Disorder |
| ALKS 5461 NCT01500200 | Phase 2 | Major Depressive Disorder |
| ALKS 5461 NCT02508506 | Phase 1 | Renal Impairment |
| ALKS 5461 NCT02452801 | Phase 1 | Hepatic Impairment |
Latest
No recent events.
Follow Alks 5461 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.